{"created":"2023-07-27T06:51:00.969063+00:00","id":44254,"links":{},"metadata":{"_buckets":{"deposit":"172d088f-cb4d-4aa4-8ef7-7974521967cc"},"_deposit":{"created_by":18,"id":"44254","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"44254"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00044254","sets":["1132:1133:1134"]},"author_link":["74458","74455","74457","74460","74461","74454","74459","70236","74456"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-08-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"870","bibliographicPageStart":"860","bibliographicVolumeNumber":"22","bibliographic_titles":[{"bibliographic_title":"Clinical and Experimental Nephrology"}]}]},"item_4_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"和田, 隆志"}],"nameIdentifiers":[{}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Hyperuricemia is supposed to be an independent risk factor for kidney dysfunction in diabetic patients. We attempted to examine the uric acid-lowering effect and the renoprotective effect of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia in this pilot study. Methods: The study design was randomized, double-blind, placebo-controlled, parallel-group study. A total of 65 patients with hyperuricemia and diabetic nephropathy with microalbuminuria were enrolled and assigned to either the topiroxostat group or the placebo group. Topiroxostat (stepwise dosing from 40 to 160 mg/day) or matching placebo was administered BID for 28 weeks. The primary endpoint was a change in the urinary albumin-to-creatinine ratio in the first-morning-void urine sample. Secondary endpoints were changes in the estimated glomerular filtration rate and the serum uric acid level. Results: At 28 weeks, there was no significant difference in the percent change from baseline in the urinary albumin-to-creatinine ratio between the two groups (topiroxostat: 0 vs. placebo: 17%, p = 0.3206), but the changes in the estimated glomerular filtration rate (− 0.2 vs. − 4.0 mL/min/1.73 m2, p = 0.0303) and the serum uric acid level (− 2.94 vs. − 0.20 mg/dL, p < 0.0001) were significantly different between the topiroxostat and placebo groups. Gouty arthritis occurred in 1 patient in the placebo group and no patients in the topiroxostat group. Conclusion: These findings support that diabetic nephropathy combined with hyperuricemia may be associated with kidney dysfunctions. Topiroxostat provides strict control of the serum uric acid level preventing decline of eGFR in these patients. © 2018 The Author(s)","subitem_description_type":"Abstract"}]},"item_4_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Embargo Period 12 months","subitem_description_type":"Other"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_4_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00050596","subitem_identifier_reg_type":"JaLC"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Tokyo"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1007/s10157-018-1530-1","subitem_relation_type_select":"DOI"}}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://www.jsn.or.jp/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.jsn.or.jp/","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"The final publication is available at www.springerlink.com/article/10.1007/s10157-018-1530-1"},{"subitem_rights":"Copyright © 2018 The Author(s)."}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA11126935","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1342-1751","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Wada, Takashi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Hosoya, Tatsuo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Honda, Daisuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sakamoto, Ryusuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Narita, Kazutaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sasaki, Tomomitsu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Okui, Daisuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kimura, Kenjiro"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-03"}],"displaytype":"detail","filename":"ME-PR-WADA-T-CEN-2018.pdf","filesize":[{"value":"133.4 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-WADA-T-CEN-860.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/44254/files/ME-PR-WADA-T-CEN-2018.pdf"},"version_id":"5478a70d-038d-4500-b708-622c8e514418"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)"}]},"item_type_id":"4","owner":"18","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-07-20"},"publish_date":"2018-07-20","publish_status":"0","recid":"44254","relation_version_is_last":true,"title":["Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T16:59:10.071001+00:00"}